

EBMT Transplantation and Cellular Therapy in Myeloid Malignancies Meeting

Paris, France | 21-22 January 2027



Acute
Leukaemia
ALWP



Chronic
Malignancies
CMWP

Thursday, 21 January 2027

09:00 – 13:00 Scientific Business Meetings

14:00 – 16:00 Session I: Novel insights on allo-HCT indications and management

Chairs: *Giorgia Battipaglia (IT) & Joanna Drozd-Sokołowska (PL)*

14:00 – 14:15 Welcome and Introduction

14:15 – 14:35 Allo-HCT Recommendation in Non-Classical MPN and MDS/MPN

14:35 – 14:55 Defining Remission and Relapse in MDS/MPN Overlaps

14:55 – 15:15 Update on Allo-HCT Indications in AML

15:15 – 15:35 Update on Allo-HCT for ALL in CR1

15:35 – 15:45 Case presentation Slot 1

15:45 – 15:55 Case presentation Slot 2

15:55 – 16:00 Discussion

Marie Robin (FR)

Eolia Brissot (FR)

Nicola Polverelli (IT)

Donal McLornan (UK)

Jordi Esteve (ES)

Sebastian Giebel (PL)

To be announced

To be announced

16:00 – 16:30 Coffee Break

16:30 – 17:15 Industry Symposium Slot

17:15 – 18:45 Session II: Session II: Allo-HCT in high-risk AML or MDS

Chairs: *Kavita Raj (UK) & Fabio Ciceri (IT)*

17:15 – 17:35 Role of Allo-HCT in High-Risk AML

17:35 – 17:55 Upfront versus Cyto-reduction before Transplant in MDS

17:55 – 18:15 Maintenance Post Allo in AML

18:15 – 18:25 Case presentation Slot 3

18:25 – 18:35 Case presentation Slot 4

18:35 – 18:45 Discussion

Annalisa Ruggeri (IT)

Marie Robin (FR)

Jaime Sanz (ES)

To be announced

To be announced

EBMT Transplantation and Cellular Therapy in Myeloid Malignancies Meeting

Paris, France | 21-22 January 2027



Acute
Leukaemia
ALWP



Chronic
Malignancies
CMWP

Friday, 22 January 2027

09:00 – 10:30 Session III: CAR-T Cell Therapy for ALL and AML/MDS: Where Do We Stand?

Chairs: Arnon Nagler (IL) & Guillermo Orti (ES)

09:00 – 09:20 Up to Date on CAR-T Therapy for AML and High-Risk MDS

09:20 – 09:40 Calreticulin-Targeted CAR T-cell Therapy in MPN

09:40 – 10:00 Update CAR-T in ALL

10:00 – 10:10 Case presentation Slot 5

10:10 – 10:20 Case presentation Slot 6

10:20 – 10:30 Discussion

Joanna Drozd-Sokołowska (PL)

Alex Rampotas (UK)

Eolia Brissot (FR)

To be announced

To be announced

10:30 – 11:30 Keynote Lecture

Chair: Marie Robin (FR)

10:30 – 11:15 Innovative therapies in myelofibrosis

11:15 – 11:30 Q&A

Jean-Jacques Kiladjian (FR)

11:30 – 12:00 Coffee Break

12:00 – 12:45 Industry Symposium Slot

12:45 – 14:15 Session IV: Post Allo-HCT Management in BCR::ABL1 mutated leukaemias

Chairs: Gesine Bug (DE) & Yves Chalandon (CH)

12:45 – 13:10 EBMT-Lead Expert Recommendation on CML Management Post Allo-HCT

13:10 – 13:35 Optimizing Management of Ph+ ALL after Transplant and CAR-T Cells

13:35 – 13:45 Case presentation Slot 7

13:45 – 13:55 Case presentation Slot 8

13:55 – 14:15 Discussion

Hugues de Lavallade (UK)

Gesine Bug (DE)

To be announced

To be announced

14:15 – 14:45 Coffee Break

14:45 – 16:50 Session V: Controversies

Chairs: Iman Abou Dalle (LB) & Christoph Scheid (DE)

14:45 – 15:40 Is It Time for PTCy to Replace ATG as the Standard GVHD Prophylaxis in Myeloid Malignancies?

14:45 – 14:55 Case presentation Slot 9

14:55 – 15:15 Yes

15:15 – 15:35 No

15:35 – 15:40 Q&A

15:45 – 16:40 Second Transplantation or DLI in Patients with MDS or AML Relapsing after Transplantation?

15:45 – 15:55 Case presentation Slot 10

15:55 – 16:15 Second allo

16:15 – 16:35 DLI

16:35 – 16:40 Q&A

16:40 – 16:50 Take Home Messages & Closing Remarks

To be announced

Patricia Chiusolo (IT)

Giorgia Battipaglia (IT)

All

To be announced

Giuliano Filippini (DE)

Christoph Schmid (DE)

All

Marie Robin (FR)

Eolia Brissot (FR)

For further information, please get in contact with education.events@ebmt.org